Financed by the National 863 Program, Tailuo TM, a patented new diabetes drug developed by the Chinese Academy of Military Medical Sciences, and manufactured by the Taiji Group, recently made its debut in the market.

As a new drug that has been put into mass production, Tailuo TM makes an innovation over the old diabetes drug Rosiglitazone Maleate. Researchers made specific calculation and analysis of the parent core of Rosiglitazone, using molecular design theory. Countless trials revealed weak acidity in the hydrogen bond of Rosiglitazon lactam. Researchers, based on the new findings, screened out a number of applicable elements, and synthesized them into the first proprietary Rosiglit-azone Sodium in the world.

The new drug has been clinically tested in a number of hospitals, including No. 1 Hospital affiliated to the Peking University, and the Ruijin Hospital, a part of Shanghai No.2 Medical School. Random and comparison testings show that Tailuo TM makes the best medicine to treat type II diabetes. Comparing with similar imported products, the Chinese made drug demonstrates its fine bio-utility for easy absorption.